Recognizing and overcoming potential barriers to oral medications for MS.
Three FDA-approved oral medications are available for the treatment of relapsing forms of multiple sclerosis: fingolimod, teriflunomide, and dimethyl fumarate. While injection and IV treatments have proven to be beneficial, these newer oral agents also offer positive outcomes for patients. Numerous barriers exist, though, for these oral agents, including the unknown long-term efficacy and safety and potential side effects. Despite possible side effects, oral agents provide convenience, ease of use, and the elimination of injection/IV administration-site pain. To ensure MS patients receive the most appropriate individualized care, clinicians should present all of the available treatment options to both newly diagnosed and established patients.
Harold
H
Moses
D000284:Administration, Oral; D003437:Crotonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D005650:Fumarates / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009570:Nitriles; D011409:Propylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D014052:Toluidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D003437:Crotonates; D005650:Fumarates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D009570:Nitriles; D011409:Propylene Glycols; D014052:Toluidines; C527525:teriflunomide; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine